Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The targeted therapies led to an 87% reduction in disease progression or death for newly diagnosed chronic lymphocytic leukemia patients.
The Leukemia & Lymphoma Society’s Lee Greenberger rounds up exciting study results from ASH 2023 and emerging themes for the future.
Approved for CLL and SLL—types of leukemia and lymphoma—Brukinsa caused fewer heart-related side effects in trials.
The Dana-Farber led ALPINE trial looked at the drug in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Immunotherapy leads the way, along with promising breakthroughs for treating leukemia and multiple myeloma.
Targeted therapy combo sent chronic lymphocytic leukemia into deep remission in people with high-risk forms of the disease.
The newer targeted therapy zanubrutinib works better and has fewer side effects than the older ibrutinib.
Study clarifies molecular pathways by which CLL transform into a more aggressive type of lymphoma.
CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.
The first two people treated with the “living drug” remained cancer-free for a decade and can be considered cured.
Studies evaluate the impact of COVID-19 infection, treatments and vaccination in this uniquely vulnerable population.
People with blood cancers and those on chemotherapy may not respond adequately to their first two vaccine doses.
A study from the Leukemia & Lymphoma Society finds that antibody production varies widely across blood cancer types.
Jennifer White, an Atlanta-based cyber security consultant diagnosed with chronic lymphocytic leukemia, shares her advocacy tips.
Tecartus led to durable remission in a majority of participants in a Phase II study.
Customized treatments demonstrate good response rates for mantle cell lymphoma and chronic lymphocytic leukemia.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.